Immunity 12 years after alemtuzumab in RA: CD5+ B-cell depletion, thymus-dependent T-cell reconstitution and normal vaccine responses

B cells expressing CD5 are increased in cerebrospinal fluidof patients with multiple sclerosis

(2010) E. MIX et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial

(2009) Clifton O. Bingham et al.   ARTHRITIS AND RHEUMATISM

Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab

(2009) Sander van Assen et al.   ARTHRITIS AND RHEUMATISM

Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: Twelve-year outcomes

(2008) Alice R. Lorenzi et al.   ARTHRITIS AND RHEUMATISM

CD5: A safeguard against autoimmunity and a shield for cancer cells

(2008) Ali Dalloul   AUTOIMMUNITY REVIEWS

Determination of thymic function directly from peripheral blood: A validated modification to an established method

(2008) A.R. Lorenzi et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

(2008)   NEW ENGLAND JOURNAL OF MEDICINE